Immunocore(IMCR) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - In 2025, the company generated $400 million in net revenue from KIMMTRAK, representing a 29% increase from the previous year [5][9][23] - The operating loss was reduced in 2025 as revenue growth outpaced operating expenses [25] - The balance sheet remains strong with approximately $864 million in cash and marketable securities, an increase of over $40 million from the previous year [8][25] Business Line Data and Key Metrics Changes - KIMMTRAK is now approved in 39 countries and launched in 30 markets, with over 70% penetration across all major markets [5][9] - The mean duration of therapy for KIMMTRAK is 14 months, exceeding clinical trial experiences [5][9] - The company activated 150 new accounts in 2025, with 70% of KIMMTRAK prescriptions coming from community settings [10][11] Market Data and Key Metrics Changes - KIMMTRAK's adoption is widespread, with half of all patient starts occurring in community settings [10] - The company expects moderating growth in 2026 due to significant market penetration [23][24] Company Strategy and Development Direction - The company is expanding KIMMTRAK's reach through a lifecycle management program with two Phase III trials: TEBE-AM and ATOM [6][7] - The oncology platform is being expanded beyond melanoma into ovarian and lung colorectal cancers [8][17] - The company aims to achieve tissue-specific down modulation of the immune system in autoimmune diseases [20] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the execution of growth strategies and the potential for KIMMTRAK to transform patient outcomes [11][26] - The company anticipates 2026 to be a year of data and continued progress, with significant readouts expected [26] Other Important Information - The company is advancing its pipeline in infectious diseases and autoimmune conditions, with promising data from ongoing studies [8][20] - The company has a robust R&D engine with three ongoing Phase III trials in oncology [13][18] Q&A Session Summary Question: Geographic breakdown of TEBE-AM enrollment - The majority of enrollment is from Europe, with 10% to 15% from the U.S. [30] Question: Treatment arms powered for overall survival in TEBE-AM - The study is designed to meet statistically significant and clinically meaningful thresholds, typically at least a 30% difference from the control [34] Question: Expectations for contract sales growth - Growth is expected to moderate as the company enters its fifth year on the market, with underlying growth around 20% after normalizing for rebate reserves [38] Question: Pricing strategy for second-line cutaneous melanoma - The company believes it can defend its pricing based on the unmet need and overall survival endpoint if data is positive [45] Question: Evaluation of success in early autoimmune studies - Success will be evaluated based on target binding and surrogate markers like C-peptide [49] Question: Learnings from KIMMTRAK's success in uveal melanoma - Half of the cutaneous melanoma patients are treated by physicians experienced with KIMMTRAK, providing a strong foundation for potential launch [52]